Completed PHASE1 INTERVENTIONAL NCT00381433

Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid

Pharmacokinetic Study of AVI-4065 in Cerebral Spinal Fluid Among Healthy Adult Males Following Subcutaneous Administration

Sponsor: Sarepta Therapeutics, Inc.

Conditions Encephalitis

Interventions AVI-4065 Injection

Updated 6 times since 2017 Last updated: Jul 6, 2009 Started: Sep 30, 2006 Primary completion: Oct 31, 2006 Completion: Jun 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Encephalitis, this trial is completed. The trial is conducted by Sarepta Therapeutics, Inc. and has accumulated 6 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Aug 2019 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Aug 2019 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Sep 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sarepta Therapeutics, Inc.

Data source: Sarepta Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tacoma, United States